Dr. Philine Ahrdorf from Lilly Germany Elected to FSA Board

Dr. Philine Ahrdorf, Head of the Medical Department at Lilly Germany, has been elected to the board of the Association for Voluntary Self-Regulation of the Pharmaceutical Industry (FSA). Since its founding 20 years ago, the FSA has promoted ethical and transparent collaboration between the pharmaceutical industry, healthcare professionals, and patient organizations.

Felix Boas, Head of Ethics and Compliance at Lilly Germany, commented: “Dr. Philine Ahrdorf’s election to the FSA board is a significant step for Lilly and the entire industry. Her commitment to high standards of integrity and responsible leadership will help further strengthen trust in the pharmaceutical sector.”

A key focus of the FSA is to foster a culture of learning and error prevention. The organization ensures that patients, physicians, and society at large can rely on a responsible and trustworthy pharmaceutical industry, grounded in voluntary self-regulation and strict adherence to codes of conduct.

Lilly has been a member of the FSA since its founding in 2004. As the association celebrates its 20th anniversary this year, it continues to play a vital role in shaping ethical standards across the industry.

With nearly 150 years of scientific innovation, Lilly is committed to improving the lives of people around the world. Today, over 51 million patients globally benefit from Lilly’s medicines, which focus on chronic conditions such as diabetes and obesity, neurodegenerative diseases like Alzheimer’s, immune disorders, and hard-to-treat cancers.

Lilly stands for medical progress with responsibility. Dr. Ahrdorf’s election to the FSA board reflects this core belief – and sends a clear message in support of transparency, ethics, and innovation in healthcare.